Biosimilar Intellectual Property Issues in the US: An Update

Posted 07 April 2017 By Raymond A. Huml, MS, DVM, RAC, Allen R. Baum, JD, Jill Dawson, PhD

placeholder+image This article provides an update on US biosimilar intellectual property issues in areas including the complex and evolving areas of patent protection, market exclusivity, the 'patent dance,' and lifecycle planning.

Share this article:

Categories: Biologics and biotechnology, Submission and registration, Features, US, FDA

Tags:

Regulatory Exchange: Latest Updates From the Community